Emerging EZH2 Inhibitors and Their Application in Lymphoma

  title={Emerging EZH2 Inhibitors and Their Application in Lymphoma},
  author={J. Lue and Jennifer E Amengual},
  journal={Current Hematologic Malignancy Reports},
  • J. Lue, Jennifer E Amengual
  • Published 2018
  • Medicine
  • Current Hematologic Malignancy Reports
  • Purpose of ReviewEnhancer of Zeste Homolog 2 (EZH2) is histone methyltransferase and catalyzes the methylation of histone 3 lysine 27, a mark of transcriptional repression. Various studies have elucidated the complex role of EZH2 in both normal biology and tumorigenesis. Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma.Recent FindingsActivating mutations and overexpression of EZH2 are… CONTINUE READING
    29 Citations
    EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
    • 12
    EZH2-Targeted Therapies in Cancer: Hype or a Reality
    • 4
    Hypomethylating Agents in Lymphoma
    Development of molecular intervention strategies for B-cell lymphoma
    β-TRCP-mediated AEBP2 ubiquitination and destruction controls cisplatin resistance in ovarian cancer.
    • 4


    Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
    • Wei Qi, H. Chan, +25 authors E. Li
    • Biology, Medicine
    • Proceedings of the National Academy of Sciences
    • 2012
    • 457
    • PDF
    Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
    • 332
    • PDF
    A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    • 602
    • PDF
    EZH2: Not EZHY (Easy) to Deal
    • 82
    • PDF